In contrast, the 5-year DFS for rectal cancer was 69.55% (95% CI, 51.81%-87.29%), for patients without CB2 expression, versus 51.14% (95% CI, 22.21%-80.1%) for patients with CB2 expression (p = 0.42). Here, CNR2 is linked to rectal cancer.